Furthermore, we present first evidence that the in vitro activity of Pazopanib and Sorafenib translates into profound anti-neoplastic efficacy in an orthotopic xenograft mouse model of the most aggressive c-myc amplified medulloblastoma variant. This evidence concerns the gene MYC and medulloblastoma.